Nephros Inc (NEPH) shareholders
Close on Nov 17, 2026Market cap $31.49MP/E 18.1Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Charles E. Davidson Joint filing with CD Holding Company, LLC (5.68%) | 616,945 | 5.68% | 13G (passive) | Sep 14, 2026 |
| Topline Capital Management, LLC Joint filing with Collin McBirney (5.60%), Topline Capital Partners, LP (5.60%) | 595,334 | 5.60% | 13G (passive) | Aug 4, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of NEPH | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Wexford Capital LP | 3,600,552 | 33.15% | $12.85M | – | 1.64% |
| Topline Capital Management, LLC | 535,698 | 4.93% | $1.91M | −46,269 | 0.50% |
| Vanguard Capital Management LLC | 198,643 | 1.83% | $709.16K | – | 0.00% |
| Morgan Stanley | 128,915 | 1.19% | $460.23K | +18,000 | 0.00% |
| Cornerstone Capital, Inc. | 128,700 | 1.19% | $459.46K | – | 0.04% |
| Bard Associates Inc | 118,003 | 1.09% | $421.27K | −3,199 | 0.09% |
| Renaissance Technologies LLC | 77,504 | 0.71% | $276.69K | −21,896 | 0.00% |
| Geode Capital Management, LLC | 70,263 | 0.65% | $250.92K | −2,662 | 0.00% |
| Mesirow Financial Investment Management, Inc. | 60,000 | 0.55% | $214.20K | −60,000 | 0.00% |
| HighTower Advisors, LLC | 59,710 | 0.55% | $213.17K | – | 0.00% |
| Navellier & Associates Inc | 53,479 | 0.49% | $190.92K | +34,353 | 0.02% |
| Essex Investment Management Co LLC | 38,927 | 0.36% | $138.97K | −57 | 0.02% |
| Vanguard Fiduciary Trust Co | 36,901 | 0.34% | $131.74K | – | 0.00% |
| Blair William & Co/Il | 36,249 | 0.33% | $129.41K | – | 0.00% |
| Citadel Advisors LLC | 29,044 | 0.27% | $103.69K | +8,156 | 0.00% |
| Dimensional Fund Advisors LP | 22,164 | 0.20% | $79.13K | +1,419 | 0.00% |
| BlackRock, Inc. | 18,822 | 0.17% | $67.20K | New | 0.00% |
| De Lisle Partners LLP | 17,400 | 0.16% | $62.12K | −7,600 | 0.01% |
| Northern Trust Corp | 16,706 | 0.15% | $59.64K | +5,878 | 0.00% |
| State Street Corp | 15,698 | 0.14% | $56.04K | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 33 | 5M | 48.9% | 7 / 7 | 9 / 1 | 0M | 0M |
| Q1 2026 | 27 | 5M | 49.4% | 3 / 6 | 9 / 10 | 1M | 0M |
| Q4 2025 | 35 | 5M | 48.8% | 14 / 11 | 5 / 3 | 0M | 0M |
| Q3 2025 | 24 | 5M | 46.2% | 4 / 4 | 9 / 1 | 0M | 0M |
| Q2 2025 | 21 | 5M | 44.7% | 4 / 8 | 5 / 1 | 0M | 0M |
| Q1 2025 | 18 | 5M | 43.0% | 1 / 5 | 5 / 1 | 0M | 0M |
| Q4 2024 | 18 | 5M | 43.4% | 3 / 2 | 7 / 2 | 0M | 0M |
| Q3 2024 | 17 | 4M | 39.5% | 0 / 5 | 6 / 2 | 0M | 0M |
| Q2 2024 | 19 | 4M | 39.9% | 4 / 5 | 6 / 3 | 0M | 0M |
| Q1 2024 | 18 | 4M | 39.4% | 3 / 8 | 3 / 3 | 0M | 0M |
| Q4 2023 | 18 | 4M | 40.2% | 4 / 6 | 2 / 0 | 0M | 0M |
| Q3 2023 | 14 | 4M | 39.5% | 1 / 3 | 3 / 3 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
15 funds held NEPH in Q2 2026, 76% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of NEPH | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 130,901 | 1.21% | $467.32K | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 67,742 | 0.62% | $241.84K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 33,707 | 0.31% | $123.37K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 17,742 | 0.16% | $63.34K | 0.00% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 11,571 | 0.11% | $42.35K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 9,528 | 0.09% | $34.87K | 0.00% | May 31, 2026 |
| Dimensional U.S. Core Equity 2 ETF | 4,811 | 0.04% | $16.31K | 0.00% | Jul 31, 2026 |
| U.S. Sustainability Core 1 Portfolio | 3,337 | 0.03% | $11.31K | 0.00% | Jul 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 3,085 | 0.03% | $11.29K | 0.00% | May 31, 2026 |
| U.S. Core Equity 2 Portfolio | 2,725 | 0.03% | $9.24K | 0.00% | Jul 31, 2026 |
| Dimensional US Core Equity 1 ETF | 2,462 | 0.02% | $8.35K | 0.00% | Jul 31, 2026 |
| U.S. Core Equity 1 Portfolio | 2,333 | 0.02% | $7.91K | 0.00% | Jul 31, 2026 |
| U.S. Social Core Equity 2 Portfolio | 2,332 | 0.02% | $7.91K | 0.00% | Jul 31, 2026 |
| U.S. Vector Equity Portfolio | 1,419 | 0.01% | $4.81K | 0.00% | Jul 31, 2026 |
| 1290 VT Micro Cap Portfolio | 1,080 | 0.01% | $3.86K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Robert R. Banks Jr. | President and CEO | 190,000 | 1.75% | Mar 25, 2026 |
| Judy Krandel | Chief Financial Officer | 68,861 | 0.63% | Mar 25, 2026 |
| Arthur H. Amron | Director | 187,683 | 1.73% | Nov 12, 2026 |
| Oliver J. Spandow | Director | 126,797 | 1.17% | Nov 12, 2026 |
| Holdings LLC Amron | Director | 187,005 | 1.72% | Sep 16, 2026 |
| Lisa Marie Nettis | Director | 1,622 | 0.01% | Nov 13, 2025 |
| Alisa Lask | Director | 48,629 | 0.45% | Jan 3, 2025 |
| Joseph Michael Harris | Director | 17,693 | 0.16% | Jan 3, 2025 |
| Charles E. Davidson | 10% owner | 3,608,667 | 33.23% | Sep 16, 2026 |
| GP LLC Wexford | 10% owner | 245,437 | 2.26% | Sep 16, 2026 |
| Capital Lp Wexford | 10% owner | 3,650,529 | 33.61% | Sep 16, 2026 |
| Joseph Jacobs | 10% owner | 30,047,742 | 276.68% | Sep 16, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Oliver J. Spandow Director | Nov 9, 2026 | Award | +3,916 | – | – | 126,797 |
| Arthur H. Amron Director | Nov 9, 2026 | Award | +3,514 | – | – | 162,137 |
| Holdings LLC Amron Director | Sep 14, 2026 | Other | +22,710 | $3.95 | $89.70K | 25,546 |
| Holdings LLC Amron Director | Sep 14, 2026 | Other | +17,749 | – | – | 158,623 |
| Holdings LLC Amron Director | Sep 14, 2026 | Other | +2,836 | – | – | 2,836 |
| GP LLC Wexford 10% owner | Sep 14, 2026 | Other | −3,355,111 | – | – | 189,377 |
| GP LLC Wexford 10% owner | Sep 14, 2026 | Other | −22,710 | $3.95 | $89.70K | 166,667 |
| Joseph Jacobs 10% owner | Aug 18, 2026 | Option exercise | +812 | $3.60 | $2.92K | 56,872 |
| Arthur H. Amron Director | Aug 12, 2026 | Award | +2,418 | – | – | 140,874 |
| Arthur H. Amron Director | May 11, 2026 | Award | +3,574 | – | – | 138,456 |
| Judy Krandel Chief Financial Officer | Mar 23, 2026 | Option exercise | +68,861 | $1.71 | $117.75K | 68,861 |
| Robert R. Banks Jr. President and CEO | Mar 23, 2026 | Option exercise | +120,000 | $1.44 | $172.80K | 190,000 |
| Arthur H. Amron Director | Mar 16, 2026 | Award | +3,610 | – | – | 134,882 |
| Lisa Marie Nettis Director | Nov 10, 2025 | Award | +1,622 | – | – | 1,622 |
| Arthur H. Amron Director | Nov 10, 2025 | Award | +5,391 | – | – | 131,272 |
| Oliver J. Spandow Director | Nov 10, 2025 | Award | +8,036 | – | – | 122,881 |
| Arthur H. Amron Director | Jan 1, 2025 | Award | +22,418 | – | – | 125,881 |
| Oliver J. Spandow Director | Jan 1, 2025 | Award | +33,241 | – | – | 114,845 |
| Arthur H. Amron Director | May 30, 2024 | Buy | +3,000 | $2.24 | $6.72K | 103,463 |
| Arthur H. Amron Director | May 28, 2024 | Buy | +2,000 | $2.22 | $4.44K | 100,463 |
| Robert R. Banks Jr. President and CEO, Director | May 16, 2024 | Buy | +50,000 | $2.24 | $112.00K | 70,000 |
| Arthur H. Amron Director | Mar 13, 2024 | Other | +91,463 | – | – | 98,463 |
| GP LLC Wexford 10% owner | Mar 13, 2024 | Other | −91,463 | – | – | 56,060 |
| Arthur H. Amron Director | Mar 12, 2024 | Buy | +7,000 | $2.45 | $17.15K | 7,000 |
| Oliver J. Spandow Director | Dec 13, 2023 | Award | +14,294 | – | – | 81,604 |
| Arthur H. Amron Director | Dec 13, 2023 | Award | +9,291 | – | – | 9,291 |
| Joseph Michael Harris Director | Dec 13, 2023 | Award | +9,291 | – | – | 17,693 |
| Alisa Lask Director | Dec 13, 2023 | Award | +9,291 | – | – | 48,629 |
| Robert R. Banks Jr. President and CEO, Director | Dec 7, 2023 | Buy | +18,000 | $2.20 | $39.60K | 20,000 |
| Robert R. Banks Jr. President and CEO, Director | Aug 15, 2023 | Buy | +1,901 | $1.69 | $3.21K | 2,000 |
| Robert R. Banks Jr. President and CEO, Director | Aug 14, 2023 | Buy | +99 | $1.50 | $149 | 99 |
| Oliver J. Spandow Director | Jan 5, 2023 | Award | +42,481 | – | – | 67,310 |
| Tom Gwydir Director | Jan 5, 2023 | Award | +27,613 | – | – | 43,226 |
| Alisa Lask Director | Jan 5, 2023 | Award | +27,613 | – | – | 39,338 |
| Joseph Michael Harris Director | Jan 5, 2023 | Award | +8,402 | – | – | 8,402 |
| Arthur H. Amron Director | Jan 5, 2023 | Award | +27,613 | – | – | 27,613 |
| Andrew Astor President, CEO & CFO, Director | Mar 5, 2022 | Option exercise | +14,815 | $2.70 | $40.00K | 92,773 |
| Wesley S. Lobo Chief Marketing Officer | Feb 16, 2022 | Tax withholding | −6,389 | $4.80 | $30.67K | 35,168 |
| Tom Gwydir Director | Dec 14, 2021 | Award | +4,582 | – | – | 15,613 |
| Arthur H. Amron Director | Dec 14, 2021 | Award | +4,582 | – | – | 4,582 |
| Alisa Lask Director | Dec 14, 2021 | Award | +4,582 | – | – | 11,725 |
| Oliver J. Spandow Director | Dec 14, 2021 | Award | +5,429 | – | – | 24,829 |
| Wesley S. Lobo Chief Marketing Officer | Aug 20, 2021 | Buy | +1,000 | $7.92 | $7.92K | 41,557 |
| Tom Gwydir Director | Aug 18, 2021 | Buy | +5,000 | $7.64 | $38.20K | 11,031 |
| Andrew Astor President & CEO, Director | Aug 18, 2021 | Buy | +2,500 | $7.77 | $19.43K | 77,958 |
| Andrew Astor President & CEO, Director | Aug 17, 2021 | Buy | +2,500 | $7.67 | $19.18K | 75,458 |
| Capital Lp Wexford Director, 10% owner | Jun 1, 2021 | Option exercise | +66,667 | $2.70 | $180.00K | 3,544,492 |
| Daron Evans CEO Specialty Renal Products | May 27, 2021 | Tax withholding | −349 | $2.70 | $942 | 8,669 |
| Daron Evans CEO Specialty Renal Products | May 27, 2021 | Tax withholding | −349 | $2.70 | $942 | 8,947 |
| Daron Evans CEO of Specialty Renal Product | May 24, 2021 | Option exercise | +1,111 | $2.70 | $3.00K | 9,018 |
| Daron Evans CEO of Specialty Renal Product | May 24, 2021 | Option exercise | +1,111 | $2.70 | $3.00K | 9,296 |
| Wesley S. Lobo Chief Marketing Officer | Feb 16, 2021 | Award | +40,557 | – | – | 40,557 |
| GP LLC Wexford Director, 10% owner | Jan 27, 2021 | Option exercise | +2,956 | $4.14 | $12.24K | 97,795 |
| GP LLC Wexford Director, 10% owner | Jan 27, 2021 | Option exercise | +3,765 | $3.60 | $13.55K | 101,560 |
| GP LLC Wexford Director, 10% owner | Jan 27, 2021 | Option exercise | +4,477 | $4.50 | $20.15K | 106,037 |
| GP LLC Wexford Director, 10% owner | Jan 27, 2021 | Option exercise | +3,556 | $4.59 | $16.32K | 94,839 |
| Arthur H. Amron Director | Jan 6, 2021 | Award | +3,666 | – | – | 3,666 |
| Alisa Lask Director | Jan 6, 2021 | Award | +3,666 | – | – | 7,143 |
| Malcolm C. Persen Director | Jan 6, 2021 | Award | +5,921 | – | – | 48,774 |
| Tom Gwydir Director | Jan 6, 2021 | Award | +3,666 | – | – | 6,031 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Nephros's stock actually held short. Settlement fails (shares not delivered on time) peaked at 1,509 shares on Aug 31, 2026 over the last 90 days.
See a number that looks wrong?